Galera Therapeutics, Inc.: 5%+ holders

As of November 10, 2026, 3 holders' latest Schedule 13D or 13G filings report owning 5% or more of Galera Therapeutics, Inc. The largest reported stake is Emerald Bioventures, LLC's, at 30.2%. 5 filings are on record since April 10, 2026 (Schedule 13D/A, May 29, 2026).

Ikarian Capital, LLC also filed stake reports on 22 other companies ↓

Sell to companies like Galera Therapeutics, Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.

Your website Find my buyers

Opens in a new tab. No signup.

Key facts

• Filing 2026-08-14 · Reporting person: Ikarian Capital, LLC · Sole voting: 0 · Shared voting: 0 · Sole dispositive: 0 · Shared dispositive: 0 · SCHEDULE 13G/A, 2026-08-14
• Filing 2026-06-11 · Reporting person: Parvinder Singh Hyare · Sole voting: 13,521,921 · Shared voting: 0 · Sole dispositive: 13,521,921 · Shared dispositive: 0 · SCHEDULE 13D, 2026-06-11
• Filing 2026-05-29 · Reporting person: Emerald Bioventures, LLC · Sole voting: 0 · Shared voting: 61,029,978 · Sole dispositive: 0 · Shared dispositive: 61,029,978 · SCHEDULE 13D/A, 2026-05-29
• Filed 2026-04-27 · Holder: Emerald Bioventures, LLC · Percent: 26.5% · SCHEDULE 13D
• Filed 2026-04-10 · Holder: Chang Nancy T · Percent: 5.9% · SCHEDULE 13D

Galera Therapeutics, Inc. has 5 Schedule 13D or 13G filings on record since 2026-04-10. 3 holders' latest filing reports 5% or more of common stock, $0.001 par value per share. Each figure below is the holder's own, as filed, with the filing linked.

Holders

Swipe the table sideways to see every column.

Holding shares or following this stake? See who's behind Galera Therapeutics, Inc. and the warning signs.

See Galera Therapeutics, Inc.'s free Snapshot Watch Galera Therapeutics, Inc.: email me the next time it files something

Free to see. No signup.

Keep reading

More on Galera Therapeutics, Inc. and the records around it.

Companies that share a holder

• Ikarian Capital, LLC also filed stake reports on 22 other companies: Quoin Pharmaceuticals Ltd. (Oct 2026), Connect Biopharma Holdings Limited (Aug 2026), InMed Pharmaceuticals Inc. (Aug 2026)

Want the whole picture on Galera Therapeutics, Inc.?

Example from a real report (our sample on Target): “In March 2026, Target announced a planned incremental $1 billion operating investment” Source: Target Corporation (press release)

A Full Report on Galera Therapeutics, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.

What the Full Report on Galera Therapeutics, Inc. covers

1. The Short Answer

2. Which Company This Is

3. What They Do, And How The Money Works

4. Who Runs It, And How To Reach Them

5. The Money: Funding, Valuation, Runway

6. Who Pays Them, And Who They Are Up Against

7. Warning Bells

8. Sources

   8 cited sources found

Plus the sections for what you are deciding, which you pick after ordering.

Order Full ReportSee a sample report

A real finished report, first screen. Opens in a new tab.

Voting and dispositive power, as filed

Swipe the table sideways to see every column.

The latest filing identifies Galera Therapeutics, Inc. by CUSIP 36338D108 and gives its principal executive office as 101 Lindenwood Dr., Suite 225, Malvern, PA 19355 (SCHEDULE 13G/A, 2026-08-14).

Source of funds (Item 3)

Item 3 of the Original 13D is supplemented and amended, as the case may be, as follows: The response to Item 4 of this Amendment No. 1 is incorporated herein by reference.Emerald Bioventures, LLC, SCHEDULE 13D/A, 2026-05-29

The response to Item 4 of this Schedule 13D is incorporated herein by reference.Parvinder Singh Hyare, SCHEDULE 13D, 2026-06-11

Purpose of Transaction (Item 4)

Chang Nancy T

The responses to Items 3 and 6 of this Schedule 13D are incorporated herein by reference. Pursuant to the Agreement and Plan of Merger, dated December 30, 2024 (the "Merger Agreement"), by and among the Issuer, Grape Merger Sub I, Inc., a Delaware corporation and a wholly owned subsidiary of the Issuer ("First Merger Sub"), Grape Merger Sub II, LLC, a Delaware limited liability company and wholly owned subsidiary of the Issuer ("Second Merger Sub"), and Nova Pharmaceuticals, Inc., a Delaware corporation ("Nova"), on December 30, 2024 (the "Closing"), the Issuer acquired Nova. In accordance with the Merger Agreement, First Merger Sub merged with and into Nova (the "First Merger"), with Nova surviving as a wholly owned subsidiary of the Issuer. Following the First Merger and as part of the same overall transaction as the First Merger, Nova merged with and into Second Merger Sub (the "Second Merger" and, together with the First Merger, the "Merger"), with Second Merger Sub being the surviving entity of the Second Merger and renamed Nova Pharmaceuticals Operating, LLC (the "Surviving Company"). At the Closing, the Reporting Person acquired 1,841.92 shares of Series B Non-Voting Convertible Preferred Stock ("Series B Preferred Stock") in exchange for shares of common stock of Nova held immediately prior to the Closing, which were automatically converted into a number of shares of Series B Preferred Stock at an exchange ratio of 177.9117. Pursuant to the Merger Agreement, …The first part of Item 4 of the SCHEDULE 13D filed 2026-04-10; the filing has the rest

Emerald Bioventures, LLC

Item 4 of the Original 13D is supplemented and amended, as the case may be, as follows: On May 14, 2026, the Issuer provided Emerald with a Notice of Mandatory Conversion of Series B Non-Voting Convertible Preferred Stock (the "Mandatory Conversion Notice") effective May 15, 2026 (the "Mandatory Conversion"). In connection with the Mandatory Conversion, 20,813.8186192892 shares of Series B Preferred Stock held by Emerald were converted into 20,813,818 shares of Common Stock. In lieu of fractional shares to which Emerald was entitled, the Company is required to pay Emerald an amount of cash equal to such fraction multiplied by the closing price of a share of Common Stock on the applicable Trading Market (as defined in the Certificate of Designation) on the date of the Mandatory Conversion, in accordance with Section 6.4.6 of the Certificate of Designation. Following the Mandatory Conversion, the Emerald now holds 61,029,978 shares of Common Stock and no shares of Series B Preferred Stock.Item 4 of the SCHEDULE 13D/A filed 2026-05-29

Parvinder Singh Hyare

The response to Item 6 of this Schedule 13D is incorporated herein by reference. Nova MergerOn December 30, 2024, the Issuer entered into an Agreement and Plan of Merger (the "Nova Merger Agreement"), by and among the Issuer, Grape Merger Sub I, Inc., a Delaware corporation and a wholly owned subsidiary of the Issuer ("First Merger Sub"), Grape Merger Sub II, LLC, a Delaware limited liability company and wholly owned subsidiary of the Issuer ("Second Merger Sub") and Nova Pharmaceuticals, Inc., a Delaware corporation ("Nova"), on December 30, 2024 (the "Closing"), the Issuer acquired Nova. In accordance with the Nova Merger Agreement, First Merger Sub merged with and into Nova (the "First Merger"), with Nova surviving as a wholly owned subsidiary of the Issuer. Following the First Merger and as part of the same overall transaction as the First Merger, Nova merged with and into Second Merger Sub (the "Second Merger" and, together with the First Merger, the "Merger"), with Second Merger Sub being the surviving entity of the Second Merger and renamed Nova Pharmaceuticals Operating, LLC (the "Surviving Company"). At the Closing, Parvinder Singh Hyare acquired 13,521.292 shares of Series B Non-Voting Convertible Preferred Stock, par value $0.001 per share ("Series B Preferred Stock"), in exchange for shares of common stock of Nova held immediately prior to the Closing, which were automatically converted into a number of shares of Series B Preferred Stock at an exchange ratio of …The first part of Item 4 of the SCHEDULE 13D filed 2026-06-11; the filing has the rest

Timeline

Swipe the table sideways to see every column.

Questions about who owns Galera Therapeutics, Inc.

Who owns Galera Therapeutics, Inc.?

On this page, 3 holders' latest ownership filings report 5% or more of Galera Therapeutics, Inc.: Emerald Bioventures, LLC (30.2%, Schedule 13D/A, filed 2026-05-29), Parvinder Singh Hyare (6.65%, Schedule 13D, filed 2026-06-11) and Chang Nancy T (5.9%, Schedule 13D, filed 2026-04-10).

Who are the largest shareholders of Galera Therapeutics, Inc.?

By the share each holder's latest filing reports, the largest holders of Galera Therapeutics, Inc. on this page are Emerald Bioventures, LLC (30.2%), Parvinder Singh Hyare (6.65%) and Chang Nancy T (5.9%).

When did Emerald Bioventures, LLC buy into Galera Therapeutics, Inc.?

The filings give report dates, not purchase dates. The earliest filing from Emerald Bioventures, LLC on this page is the Schedule 13D, filed 2026-04-27, reporting 26.5%; its latest, Schedule 13D/A filed 2026-05-29, reports 30.2%.

Is this an audit or a full list?

Neither. The ownership list on this page covers only Schedule 13D and 13G filings, which holders make once they own 5% or more of a class of shares (an amendment can report a stake that has since fallen below 5%); 5 such filings are shown here. It is not an audit and not a full cap table: holders who never reached 5% are not listed, and a stake can change after its latest filing.

Also on the record for Galera Therapeutics, Inc.

Swipe the table sideways to see every column.

Tools for this story

Each opens in a new tab, filled in for Galera Therapeutics, Inc.. With no account yet, you sign up free and land on the result.

• Get an alert when Galera Therapeutics, Inc. is mentioned again
• Find former Galera Therapeutics, Inc. employees to interview
• Verify a claim or statistic

Where this comes from

Anyone who comes to own more than 5% of a class of a listed company's voting shares has to tell the SEC. A holder who may seek to change or influence the company files Schedule 13D, and has to say in Item 4, "Purpose of Transaction", what it intends to do. A holder with no such intent, such as many index and passive funds, may file the shorter Schedule 13G. Both are amended when the stake changes, including when it falls below 5%.

Every row here is one of those filings, linked to the filing itself. Percentages and share counts are exactly as the holder filed them, for the holder the filing names; an amendment showing a lower figure is shown as filed. Item 4 text is quoted word for word. Where a 13D's Item 4 contains a sentence stating a definite intent to influence the company, that sentence is marked and quoted; the page does not describe the holder or its motives beyond the words it filed. Nothing here is investment advice.

All recent stakesThat week's stakes